Details for New Drug Application (NDA): 216727
✉ Email this page to a colleague
NDA 216727 describes PRAZOSIN HYDROCHLORIDE, which is a drug marketed by Alembic, Am Therap, Ani Pharms, Appco, Aurobindo Pharma Ltd, Dava Pharms Inc, Granules, Lannett Co Inc, Mankind Pharma, MSN, Mylan, Novitium Pharma, Purepac Pharm, Teva Pharms, and Watson Labs, and is included in twenty-three NDAs. It is available from twenty-seven suppliers. Additional details are available on the PRAZOSIN HYDROCHLORIDE profile page.
The generic ingredient in PRAZOSIN HYDROCHLORIDE is prazosin hydrochloride. There are seventeen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the prazosin hydrochloride profile page.
The generic ingredient in PRAZOSIN HYDROCHLORIDE is prazosin hydrochloride. There are seventeen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the prazosin hydrochloride profile page.
Summary for 216727
| Tradename: | PRAZOSIN HYDROCHLORIDE |
| Applicant: | Msn |
| Ingredient: | prazosin hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 216727
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 1MG BASE | ||||
| Approval Date: | Sep 17, 2024 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 2MG BASE | ||||
| Approval Date: | Sep 17, 2024 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 5MG BASE | ||||
| Approval Date: | Sep 17, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
